Search results
Results From The WOW.Com Content Network
The Misuse of Drugs Act 1973 is a statute of the Parliament of Singapore that enables authorities to prosecute offenders for crimes involving illegal drugs.The law is designed specifically to grant the Government of Singapore, through its agencies such as the Central Narcotics Bureau, enforcement powers to combat offences such as the trafficking, importation or exportation, possession, and ...
This is the list of Schedule I controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a high potential for abuse. The drug or other substance has no currently accepted medical use in ...
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a high potential for abuse. The drug or other substance has a currently accepted medical use in ...
List of Schedule III controlled substances (U.S.) This is the list of Schedule III controlled substances in the United States as defined by the Controlled Substances Act at 21 U.S.C. § 812 (c) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule: [1]
Oxycodone is a controlled substance under Schedule I of the Controlled Drugs and Substances Act (CDSA). Canadian oxycodone HCL/acetaminophen 5/325 mg tablet. In February 2012, Ontario passed legislation to allow the expansion of an already existing drug-tracking system for publicly funded drugs to include those that are privately insured.
Certolizumab pegol. Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease, [2] [3] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.
On 24 April 2007 the U.S. Food and Drug Administration advisory panel reviewing maraviroc's New Drug Application unanimously recommended approval for the new drug, and the drug received full FDA approval on 6 August 2007 for use in treatment experienced patients.
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...